Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPETE: 177Lu-edotreotide versus everolimus in progressive SSTR-positive GEP-NET
NL-OMON60196Phase 3Active, not recruiting
- Sponsor
- ITM Isotope Technologies Munich
- Start
- Mar 2018
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Gastroenteropancreatic Carcinoid Tumor comparing 177Lu-edotreotide with everolimus (2 arms). Primary endpoint: Progression-free survival. Started Mar 2018; status: active, not recruiting.
02
Drugs
lutetium Lu 177-edotreotideeverolimus
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on NL-OMON60196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60196.